Evidence map›Paper›PMID 36415144›Full record

ArticleClinical and translational science2023

Antidepressant drug-drug-drug interactions associated with unintentional traumatic injury: Screening for signals in real-world data.

Cheng Chen, Sean Hennessy, Colleen M Brensinger, Warren B Bilker, Sascha Dublin, Sophie P Chung, John R Horn, Kacie F Bogar, Charles E Leonard

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Therapeutic drug monitoring in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Cheng ChenCenter for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3240-8153
Sean HennessyCenter for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Colleen M BrensingerCenter for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Warren B BilkerCenter for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sascha DublinKaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Sophie P ChungEpocrates Medical Information, AthenaHealth, Inc., Watertown, Massachusetts, USA.ORCID 0000-0003-1520-2898
John R HornDepartment of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Kacie F BogarCenter for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Charles E LeonardCenter for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-5092-9657
Center for Clinical Research (United States) · USathenahealth · USKaiser Permanente Washington Health Research Institute · USTranslational Therapeutics (United States) · USUniversity of Washington · US

Funding

Clinical Importance of Drug-Drug InteractionsR01AG025152 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN, LI, LANG · 2006 to 2021
$8.1M
Drug interactions involving psychoactive drugsR01AG060975 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Charles Edward Leonard · 2019 to 2026
$3.9M
Drug-Drug Interactions Involving Methadone and BuprenorphineR01DA048001 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN · 2019 to 2023
$2.9M
Enhancing the Utility of the Trend-in-Trend Research DesignR01AG064589 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN, SMALL, DYLAN S · 2019 to 2022
$2.2M
NIA NIH HHS R01 AG025152NIA NIH HHS R01 AG060975NIDA NIH HHS R01 DA048001
6 · The paper itself

Abstract

Antidepressants are associated with traumatic injury and are widely used with other medications. It remains unknown how drug-drug-drug interactions (3DIs) between antidepressants and two other drugs may impact potential injury risks associated with antidepressants. We aimed to generate hypotheses regarding antidepressant 3DI signals associated with elevated injury rates. Using 2000-2020 Optum's de-identified Clinformatics Data Mart, we performed a self-controlled case series study for each drug triad consisting of an antidepressant + codispensed drug (base-pair) with a candidate interacting medication (precipitant). We included persons aged greater than or equal to 16 years who (1) experienced an injury and (2) used a candidate precipitant, during base-pair therapy. We compared injury rates during observation time exposed to the drug triad versus the base-pair only, adjusting for time-varying covariates. We calculated adjusted rate ratios (RRs) using conditional Poisson regression and accounted for multiple comparisons via semi-Bayes shrinkage. Among 147,747 eligible antidepressant users with an injury, we studied 120,714 antidepressant triads, of which 334 (0.3%) were positively associated with elevated injury rates and thus considered potential 3DI signals. Adjusted RRs for signals ranged from 1.31 (1.04-1.65) for sertraline + levothyroxine with tramadol (vs. without tramadol) to 6.60 (3.23-13.46) for escitalopram + simvastatin with aripiprazole (vs. without aripiprazole). Nearly half of the signals (137, 41.0%) had adjusted RRs greater than or equal to 2, suggesting strong associations with injury. The identified signals may represent antidepressant 3DIs of potential clinical concern and warrant future etiologic studies to test these hypotheses.

Indexed as

TramadolAgedAntidepressive AgentsAripiprazoleBayes TheoremDrug InteractionsHumansAntidepressive AgentsAripiprazoleTramadol

Identifiers

PMID36415144
PMCPMC9926061
OpenAlexW4309707645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.